MetaCap

Polaryx Therapeutics (PLYX) vs vTv Therapeutics (VTVT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Polaryx Therapeutics is the larger company by market cap ($66.3 million vs $62.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PLYX-96.20%VTVT-59.51%
+13%-44%-101%
Feb 2, 20261 yearNov 20, 2026
PLYX-85.07%VTVT-46.55%
+48%-22%-91%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PLYX versus VTVT key metrics
MetricPLYXVTVT
Share price$1.33$15.51
Market cap$66.30M$62.22M
1-day change-11.92%-5.20%
YTD return—-61.22%
1-year return—-47.53%
5-year return—-71.06%
EPS (TTM)$-0.18$-0.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-8.98M$-26.97M
52-week high$48.91$44.00
52-week low$1.30$15.47
Distance from 52-week high-97.28%-64.75%
Analyst consensusnonestrong_buy
Avg. price target upside+463.91%+261.06%
Average volume36.42K33.07K
Shares outstanding49.85M4.01M
Employees226
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Polaryx Therapeutics

PLYX stock →

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

About vTv Therapeutics

VTVT stock →

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees

PLYX vs VTVT FAQ

Which is bigger, Polaryx Therapeutics or vTv Therapeutics?

Polaryx Therapeutics (PLYX) is larger, with a market capitalization of $66.30M compared with $62.22M for vTv Therapeutics (VTVT).

Are Polaryx Therapeutics and vTv Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons